Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Would Other Caregivers Recommend Cannabis for Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

When families turn to cannabis-based medicinal products (CBPMs) for dementia, their decisions are often shaped as much by other caregivers’ experiences as by clinical advice. Online forums, support groups, and early research studies reveal mixed perspectives; some report calmer moods and better sleep, while others express caution over side effects and the lack of formal guidance. 

According to NHS England and NICE guidance NG144, CBPMs are not licensed for dementia. Prescribing is limited to specialists for conditions such as epilepsy, spasticity, and chemotherapy-related nausea. However, in private or research settings, caregivers have been key observers of how cannabis influences daily life and behaviour in people with dementia. 

Can medical cannabis be accessed legally for women’s health?

What Caregivers Have Reported in Studies 

A 2024 Frontiers in Aging Neuroscience study found that caregivers noticed less agitation, improved sleep, and reduced distress when patients used CBD-rich oil under clinical supervision. Nearly two-thirds said they would recommend such treatment if managed by a qualified specialist. 

In Israel’s 2024 cohort study, most family carers described calmer communication, better social interaction, and easier daily routines after supervised cannabis use. However, some reported short-term drowsiness or confusion during the first few weeks of treatment. 

Similarly, a 2023 Australian crossover trial found that caregivers valued the reduction in agitation and nighttime disruption but emphasised that medical oversight and education were essential for safety. The BMJ’s 2023 review echoed that while caregiver satisfaction is growing, the evidence base is still modest and should not replace established dementia therapies. 

Safety, Supervision, And Ethical Context 

Under the Human Medicines Regulations 2012, cannabis prescribing in older adults requires specialist supervision and informed consent. The MHRA warns that sedation, balance issues, and confusion remain possible in elderly patients, so dose titration and monitoring are vital. 

Most caregivers who support cannabis use emphasise that positive experiences came from clinically guided regimens, not from over-the-counter products or self-medication.  

Clinical Bottom Line 

  • Many caregivers report calmer behaviour and better sleep with supervised cannabis use. 
  • NICE and NHS England do not approve cannabis for dementia. 
  • CBPMs must be prescribed and monitored by a specialist clinician. 
  • Evidence suggests caregiver satisfaction, but findings remain limited. 
  • Professional oversight and education are essential for safety. 

Role Of AlleviMed 

Educational services such as AlleviMed provide families with clear, factual guidance on medical cannabis regulation in the UK. They explain eligibility requirements, safety monitoring, and caregiver responsibilities. AlleviMed does not prescribe or promote treatment but supports informed, ethical decision-making for families exploring CBPMs under medical supervision. 

Takeaway 

Most caregivers who recommend cannabis for dementia do so because they have seen calmer, less agitated behaviour under close supervision. Yet professionals caution that cannabis is not an approved dementia treatment, and benefits can vary widely. Caregivers considering this path should always involve a qualified specialist and rely on clear clinical guidance rather than anecdotal reports. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories